SHANDONG WEIGAO GROUP MEDICAL POLYMER COMPANY LIMITED

Biosensors International Group, Ltd. ("

The net tangible asset value attributable to the 10% equity interest to be acquired by Biosensors will be approximately RMB 2.269 million determined on the basis of the audited net tangible assets of JW Medical for its most recent completed financial year ended 31 December 2005 which were RMB 22.69 million. In consideration for such equity interest, Biosensors will enter into a license agreement with JW Medical to license certain of its drug-eluting stent technology to JW Medical on a non-exclusive basis, including its biodegradable polymer, polymer free technology and Biolimus A9. Biosensors will not pay any cash consideration for such acquisition. Biosensors believes that this arrangement will allow both parties to leverage on their mutual strengths – Weigao will have use of the latest drug-eluting stent technology and Biosensors will be able to leverage on Weigao’s existing distribution network in China. Together they will be better positioned to penetrate the growing drug-eluting stent market in China.

The Letter of Intent also provides that Biosensors will have an option to acquire an additional 10% equity interest in JW Medical from the two existing shareholders of JW Medical, for an aggregate consideration calculated at the higher of (i) US$10 million or (ii) 10% of 4 times the actual revenues of JW Medical for the calendar year 2007. Such consideration may be satisfied either in cash or by way of new shares to be issued by Biosensors, at the option of such selling shareholders, which will be made in accordance with the requirements of the listing rules of the Singapore Exchange Securities Trading Limited (“

The Letter of Intent also provides that Biosensors and Weigao will streamline their existing joint-venture manufacturing operation in China (“

Biosensors has, together with Weigao, released a joint press release today. A copy of thejoint press release is attached to this announcement for reference.

Issued byBIG") is pleased to announce that it has entered into a Letter of Intent (the “Letter of Intent”) with Shandong Weigao Group Medical Polymer Company Limited (“Weigao”) to explore opportunities for collaboration between the two companies. Biosensors will be negotiating definitive agreements with Weigao and JW Medical System Limited (“JW Medical”), a privately owned drug-eluting stent company in China which is 50 percent owned by Weigao, pursuant to which Biosensors will acquire a 10% equity interest in JW Medical.SGX-ST”), including, if necessary, any requirements to seek the approval of shareholders under Chapter 10 of the SGX-ST Listing Manual.Weigao Biosensors”) that was formed in 2003 between the parent company of Weigao and Biosensors International Pte Ltd, a subsidiary of Biosensors. JW Medical will acquire a 50% equity interest in Weigao Biosensors from the parent company of Weigao and a 1% equity interest in Weigao Biosensors from BSI, thereby resulting in an equity position in Weigo Biosensors of 51%, with the remaining 49% owned by BSI. Weigao Biosensors will continue to focus on the manufacturing of critical care products capitalizing on cost effectiveness through enhanced operations in China while also capitalizing on JW Medical's direct sales force to expand its channels of distribution, including distributing the full range of critical care catheter systems.

BIOSENSORS INTERNATIONAL GROUP, LTD.

Yang Joo Chua

Secretary

1 November 2006